batanopride

10/01/1991 - "One of these agents, batanopride, produced no severe toxicity at doses that prevented emesis due to chemotherapy in early Phase I trials. "
06/01/1990 - "Effects of zacopride and BMY25801 (batanopride) on radiation-induced emesis and locomotor behavior in the ferret."
10/01/1991 - "We conducted a randomized, double-blinded, 7 arm clinical trial to: (1) identify the presence of a dose-response for complete protection from emesis, and (2) compare batanopride with a standard antiemetic, methylprednisolone if a dose-response was found not to exist. "
01/01/1991 - "Of 15 evaluable patients, 8 experienced less than or equal to 2 episodes of emesis within 24 h of the first batanopride infusion, whereas 9/15 subjects experienced less than or equal to 2 emetic episodes following the administration of metoclopramide. "
01/01/1991 - "Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis."

01/01/1991 - "Although we observed no hypotension following treatment with batanopride in this trial, we did note asymptomatic prolongation of the corrected QT interval (QTc), PR interval, and QRS complex on the EKG in the batanopride arm. "
01/01/1991 - "The study was terminated when hypotension was observed following the infusion of batanopride at other institutions testing similar drug schedules. "
02/01/1991 - "Dose-limiting hypotension with the 5-HT3-antagonist batanopride (BMY-25801)."
10/01/1991 - "While the highest batanopride dose group was associated with a higher complete protection rate (CPR) than the control group, this group also exhibited a higher incidence of diarrhea (p = 0.013), hypotension, and electrocardiographic abnormalities.(ABSTRACT TRUNCATED AT 250 WORDS)"

09/01/1990 - "Batanopride (BMY-25801): a new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis."

10/01/1991 - "While the highest batanopride dose group was associated with a higher complete protection rate (CPR) than the control group, this group also exhibited a higher incidence of diarrhea (p = 0.013), hypotension, and electrocardiographic abnormalities.(ABSTRACT TRUNCATED AT 250 WORDS)"

03/01/1988 - "BMY-25801 failed to reveal any D2-dopamine receptor antagonist properties in several pharmacological tests (catalepsy, apomorphine stereotypy, serum prolactin, striatal dihydroxyphenylacetic acid and [3H]spiperone displacement) whereas metoclopramide was uniformly active in these tests. "